An evening walk down D-St: Indian market rises for 2nd day in a row Among the secondary indices, BSE Midcap outperformed Sensex, rising 0.44 percent while Smallcap index underperformed, ending with a mild gain of 0.12 percent.
YE FAKE SCREENSHOT POST KARTE HAIN .Ye commodity biz scam hai bhai log inki baat pe bilkul bhi trade mat karna in logon ko kuch bhi nhi aata . In logon ne mera 60000 RS chori kar lia ye log chor hai scammers hain . Agar apna paisa bachana hai to in scammers logon se door rehna .
Morgan Stanley bullish on these 2 pharma stocks which could give 32-47% return Morgan Stanley also has overweight rating on Lupin with a target price at Rs 1,003, implying 47 percent potential upside from current levels as it believes the share price will rise in absolute terms over the next 30 days.
Indian pharma market sees growth of 11.5% in Q2FY20 The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Indian pharma market registers growth of 11.5% in Q2FY20 The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
An evening walk down D-St: Market falls for 2nd straight day; banks, financials top drag Investors kept their bets low amid lack of fresh triggers at home and mixed global cues, while rupee's slide against the US dollar weighed on sentiment.
Corporate Tax Cut | Companies to gain Rs 44,000 crore from deferred tax liabilities: Report Reliance Industries and ONGC are the biggest gainers as each stand to gain over Rs 13,000 crore because of deferred tax
What should investors buy now? 25 Nifty50 stocks trading at a premium to their 10-yr average Experts feel that the premium given to the stocks is justified, and will continue to dominate the space as they can be termed ‘safe bets’ in volatile times.